MSF report shows price of older HIV drugs decreasing

Trade agreements and pressure on India’s ‘pharmacy of the developing world’ pose major threats to access

hiv-drug

(Photo Courtesy: www.topnews.in)

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) released the 18th edition of its HIV drug pricing report, Untangling the Web of Antiretroviral Price Reductions, at the International AIDS Conference in Durban, South Africa.

The report finds that prices of older HIV drugs continue to decline, while newer drugs remain largely priced out of reach of the people who need them most.

This is in large part because pharmaceutical corporations maintain monopolies that block price-lowering generic competition.

Today, the lowest available price for a quality-assured, World Health Organization-recommended first-line one-pill-a-day combination is $100 per person per year (tenofovir/emtricitabine/efavirenz).

This is a decrease of 26 percent since MSF last recorded the lowest price for first-line treatment at $136 in 2014.

 

Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X